Dr Asma Rezig

Asma Oumkaltoum Rezig is a pharmacist, immunologist, and translational cancer researcher specialising in evidence synthesis and clinical research. She completed her PhD in 2024 at the University of Glasgow’s Cardiovascular Immunology lab (https://theses.gla.ac.uk/id/eprint/84446), where she played a key role in integrating evidence synthesis with translational cardiovascular research. As an Honorary Researcher at NHS Greater Glasgow and Clyde, she contributed to clinical studies investigating the role of immune response across the cardiovascular and cardio-oncology spectrum, including the QUEST-HF experimental trial (NCT05090137) and the BIOCAPRI study (NCT06597045). In addition to clinical research, Asma has authored multiple systematic reviews and meta-analyses on healthcare interventions and biomarkers. She has expertise across all stages of the evidence synthesis process, from protocol development to data synthesis. In 2025, Asma joined the Centre for Cancer Genetic Epidemiology (CCGE) as a Research Associate in Evidence Synthesis. Her current research focuses on understanding the role of different biomarker modalities in tumour progression, in line with the NHS Long Term Plan in early cancer detection.